Chemed/$CHE
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Chemed
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
- Ticker
- $CHE
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 15,811
- Headquarters
- Cincinnati, United States
- Website
- www.chemed.com
Chemed Metrics
BasicAdvanced
$6.5B
25.15
$19.91
0.51
$2.50
0.56%
Price and volume
Market cap
$6.5B
Beta
0.51
52-week high
$557.00
52-week low
$365.21
Average daily volume
149K
Dividend rate
$2.50
Financial strength
Current ratio
0.911
Quick ratio
0.716
Long term debt to equity
0.305
Total debt to equity
0.355
Dividend payout ratio (TTM)
12.07%
Interest coverage (TTM)
108.20%
Profitability
EBITDA (TTM)
416.918
Gross margin (TTM)
33.11%
Net profit margin (TTM)
10.60%
Operating margin (TTM)
13.67%
Effective tax rate (TTM)
25.51%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
13.45%
Return on equity (TTM)
27.11%
Valuation
Price to earnings (TTM)
25.148
Price to revenue (TTM)
2.664
Price to book
7.94
Price to tangible book (TTM)
125.6
Price to free cash flow (TTM)
21.359
Free cash flow yield (TTM)
4.68%
Free cash flow per share (TTM)
23.439
Dividend yield (TTM)
0.50%
Forward dividend yield
0.56%
Growth
Revenue change (TTM)
3.31%
Earnings per share change (TTM)
2.22%
3-year revenue growth (CAGR)
5.87%
10-year revenue growth (CAGR)
5.18%
3-year earnings per share growth (CAGR)
9.91%
10-year earnings per share growth (CAGR)
12.18%
3-year dividend per share growth (CAGR)
16.45%
10-year dividend per share growth (CAGR)
9.60%
What the Analysts think about Chemed
Analyst ratings (Buy, Hold, Sell) for Chemed stock.
Analyst projections of the future price of Chemed stock.
Bulls say / Bears say
VITAS has returned to strong growth after the Florida Medicare-cap disruption. Second-quarter patient revenue rose 11.9%, admissions rose 9.0%, and Chemed raised its 2026 VITAS census and revenue-growth guidance. (Chemed Corporation, Chemed Corporation Q2 2026 10-Q)
VITAS is showing meaningful operating leverage as cap pressure eases. Second-quarter adjusted EBITDA excluding the Medicare cap rose 20.6%, margin expanded by 196 basis points, and full-year adjusted EPS guidance was raised to $25.00–$25.75. (Chemed Corporation, Chemed Corporation Q2 2026 10-Q)
Roto-Rooter has stabilised enough to remain a useful cash-generating base while VITAS grows. Commercial sales were strong, management is pursuing further franchise acquisitions, and the company continues to have capital for acquisitions and share repurchases. (Jefferies Healthcare Services and Technology Conference transcript, Chemed Corporation)
Roto-Rooter faces a structural customer-acquisition problem: free internet leads have fallen sharply, while paid leads cost more. Total leads fell 1.6% in the second quarter and higher marketing spend helped push adjusted EBITDA margin down to 21.1%. (Jefferies Healthcare Services and Technology Conference transcript, Yahoo Finance)
VITAS remains exposed to Medicare payment rules and the annual hospice cap. Chemed reduced its expected 2026 cap-related billing limitation to $7 million, but the 10-Q says it must still monitor programmes and estimate repayments if corrective action fails. (Chemed Corporation, Chemed Corporation Q2 2026 10-Q)
Roto-Rooter’s underlying execution is mixed rather than clearly recovering: water-restoration revenue fell 6.7%, independent-contractor revenue fell 1.9%, and quarterly adjusted EBITDA was flat. That leaves Chemed relying heavily on VITAS to offset weakness in its second-largest segment. (Yahoo Finance, Alphastreet)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
Chemed Financial Performance
Revenues and expenses
Chemed Earnings Performance
Company profitability
Upcoming events
No upcoming events
Chemed News
AllArticlesVideos
Funds containing Chemed
AllUSDEURGBP
Fund name | Fund size | $CHE weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.55% |
iShares Ageing Population€AGED | €822M | 0.55% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.19% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.19% |
iShares MSCI World Small Cap$WSML | $9B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.